A-B. Groups of 8–12 C57/BL6 mice were sourced from Taconic and subcutaneously injected with 2×106 MC38 cells. After tumors were measured on day 7, mice were randomized (58 mm3 mean tumor volume per group) and then treated with the designated mAb (200 μg/dose IP) followed by additional doses on days 10, 14, and 17. A. Groups were treated with 4 doses of single or combined agents. Anti-PD-1 vs control p = 0.0176; anti-PD-1 and anti-CTLA-4 vs control p< 0.0001. B. Sequential dosing, where 4 doses were given as 2 doses of one mAb followed by 2 doses of the other mAb and the converse. Anti-CTLA-4 followed by anti-PD-1 vs control p = 0.0250; anti-PD-1 followed by anti-CTLA-4 vs control p = 0.0015. Tumor volumes were measured twice weekly. The number of tumor-free (TF) mice per group is indicated. C-D. Groups of 10 BALB/c mice sourced from CRL (C) or HAR (D) Laboratories were subcutaneously injected with 1×106 CT26 cells. After tumors were measured on day 7, mice were randomized (C: 56 mm3 and D: 35 mm3 mean tumor volume) and then treated with the designated mAb (200 μg/dose IP) followed by additional doses on days 10, 14 (HAR mice), or 10, 14, 17 (CRL mice). Anti-CTLA-4 vs control p = 0.0035; anti-CTLA-4 and anti-PD-1 vs control p<0.0001. Tumor volumes were measured twice weekly. The number of TF mice per group is indicated.
Citation: Selby MJ, Engelhardt JJ, Johnston RJ, Lu L-S, Han M, Thudium K, et al. (2016) Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS ONE 11(11): e0167251. https://doi.org/10.1371/journal.pone.0167251
Published: November 18, 2016
Copyright: © 2016 Selby et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.